BIBW 2992 (afatinib)

afatinib · Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BIBW 2992 (afatinib), covering 2013-10-14 to 2013-10-14. Get the full timeline:

Most recent: Clinical Trial Update: An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer [Phase 2]